Every day at Foundation Medicine, our goal is to help advance the global understanding of cancer in order to transform patient care. We are driven by a commitment to help each person diagnosed with cancer realize the potential benefits of precision medicine; to support physicians in making informed treatment decisions; and, to accelerate the development of new innovative treatments.
Today, we took a significant step in advancing our mission by contributing 18,000 genomic profiles from our FoundationInsightsTM knowledgebase to the National Cancer Institute’s Genomic Data Commons portal (GDC). This HIPAA-compliant contribution of de-identified information from real-word clinical profiles will more than double the size of NCI’s GDC database and complement the research information it currently contains. We’re honored to be the first commercial entity to contribute genomics data to the NCI – – a recognition which we believe is a testament to the quality, integrity and richness of Foundation Medicine's genomic information. More importantly, we’re humbled to make such a significant contribution to advance cancer care and to provide information that can help accelerate the development of new treatments.
Our collaboration with the NCI marks the second public release of information from FoundationInsights this year. In February, we released HIPAA-compliant information for pediatric clinical samples to stimulate global development of precision therapies that fight cancer in children. This data exchange—and the one we’ve just made—are part of our ongoing commitment to the Cancer Moonshot, a federal initiative to double the rate of progress in cancer prevention, diagnosis and treatment over the next five years.
It’s inspiring to participate in an initiative at this scale, knowing that we share a vision of accelerated research with the global oncology community, including physicians, researchers, patients, advocates and survivors. We’re hopeful that the insights gleaned from this data release will prove invaluable in advancing our collective effort to inform new research and stimulate the discovery of novel innovations to fight cancer.